Skip to main content

Advertisement

Table 1 Association of demographic and clinico-pathological characteristics with expression levels of Bax, Bcl-2 and Bcl-XL

From: Bax expression measured by AQUAnalysis is an independent prognostic marker in oral squamous cell carcinoma

  N=69   Univariate Analysis Baxa n=64 Bcl-2a n=63 Bcl-XLa n=63
  # OF CASES (%) Hazard Ratio 95% CI p-value Low High p-value Low High p-value Low High p-value
GENDER    1.72 0.693 - 4.286 0.24    0.419    0.109    0.419
Male 49 71.01     20 24   18 25   20 23  
Female 20 28.99     12 8   13 7   12 8  
AGE b    1.35 0.543 - 3.364 0.52    1.000    0.315    0.616
<60 years 29 42.03     15 14   12 17   16 13  
≥60 years 40 57.97     17 18   19 15   16 18  
pT STATUS    2.55 1.022 - 6.357 0.05    0.616    0.207    0.616
1 + 2 38 55.07     19 16   20 15   19 16  
3 + 4 31 44.93     13 16   11 17   13 15  
pN STATUS    7.470 2.467 - 22.611 <0.0001    0.315    0.802    1.000
N0 39 56.52     15 20   16 18   17 17  
N1 + N2 30 43.48     17 12   15 14   15 14  
SMOKING HISTORY    0.65 0.245 - 1.702 0.38    0.075    0.148    0.237
Never 15 21.74     11 4   10 5   10 5  
Ever 54 78.26     21 28   21 27   22 26  
ALCOHOL HISTORY    0.46 0.162 - 1.282 0.14    1.000    1.000    1.000
Never 11 17.46     5   4 4 5   5 4  
Ever 52 82.54     27 23   23 26   24 24  
TUMOUR DIFFERENTIATION    1.62 0.772 - 3.427 0.2    1.000    0.923    0.525
Well 14 22.95     7 6   6 7   8 5  
Moderate 38 62.30     18 18   19 16   15 20  
Poor 9 14.75     4 3   4 3   3 4  
TREATMENT    2.16 0.629 - 7.412 0.22    0.257    0.011    0.164
Surgery 18 26.09     6 11   13 4   6 11  
Surgery + RXT 51 73.91     26 21   18 28   26 20  
STAGE    4.68 1.358 - 16.087 0.01    1.000    0.797    1.000
I + II 26 37.68     11 12   12 11   12 11  
III + IV 43 62.32     21 20   19 21   20 20  
PROLIFERATION (Ki67)    0.6 0.231 - 1.539 0.29    0.001    0.617    0.211
Low 32 50.00     23 9   17 15   19 13  
High 32 50.00     9 23   14 17   13 18  
  1. aCut-point selected at median.
  2. bMedian value.